Lv2
174 积分 2025-04-16 加入
First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens
1个月前
已完结
Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis
2个月前
已关闭
Retromomelo: Real-world use of momelotinib – the french experience from the FIM group
2个月前
已关闭
Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
2个月前
已完结
Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta‐Analysis and Matching‐Adjusted Indirect Comparison
2个月前
已关闭
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
2个月前
已完结
Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
2个月前
已完结
Phase II Single Center Prospective Study of Ruxolitinib in Addition to Standard Graft Versus Host Disease Prophylaxis in Patients with Myelofibrosis Demonstrates Encouraging Outcomes
5个月前
已完结
Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
5个月前
已关闭
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis
8个月前
已关闭
皖公网安备34019202002308
